RE:RE:RE:RE:RE:RE:BNN Coverage of New CEOI don't think anyone thinks the institutional shorts will leave this alone anytime soon, doesn't mean there isn't upside from here though.
This solution to the is to issue a generic. Amco controls a monopoly over Liothryonine, I don't see the UK government being as draconian as people assume they will be.
Also important to note that CXR has access to a broad market, and no single drug represents more than 2% or so of revenues. So, these headwinds can be mitigated to a degree.
This entire issue is very complex, and is why the stock valuation of CXR has been knocked down so much.